Home > Breast Cancer Information > Facts & Statistics > Research Studies > Research Table Topics > Vepdegestrant (Veppanu) for Metastatic Breast Cancer

Research table: Vepdegestrant (Veppanu) for metastatic breast cancer treatment

This summary table contains detailed information about research studies. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. However, to get the most out of the tables, it’s important to understand some key concepts. Learn how to read a research table.

Introduction: Proteolysis-targeting chimera (PROTAC) estrogen receptor degraders are a type of hormone therapy. They break down estrogen receptors found on hormone receptor-positive cancer cells.

The PROTAC estrogen receptor degrader vepdegestrant (Veppanu) is used to treat hormone receptor-positive, HER2-negative metastatic breast cancers that have an ESR1 tumor gene mutation and have been treated with hormone therapy and a CDK4/6 inhibitor in the metastatic setting.

The ESR1 mutation is in the genes of the breast cancer cells, not the genes of the person. The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend all hormone receptor-positive, HER2-negative metastatic breast cancers be tested for ESR1 tumor gene mutations [1-2].

Learn more about vepdegestrant, including its side effects.

Learn about guidelines for the treatment of metastatic breast cancer.

Learn about the strengths and weaknesses of different types of studies.

Study selection criteria: Randomized clinical trials with 200 or more participants with hormone receptor-positive, HER2-negative metastatic breast cancer.

Study

Study Population
(number of participants)

Drug(s) Used

Objective Response Rate—Percent who Responded to Treatment
(95% CI)

Progression-free Survival (survival with no breast cancer spread) better with vepdegestrant compared to fulvestrant?

Randomized clinical trials

VERITAC-2 Study Group [1]

270*

Vepdegestrant

19%†

Yes†

 

 

Fulvestrant

4%†

* All participants had breast cancer with a ESR1 tumor gene mutation

† Statistically significant difference between the 2 treatment groups

References

  1. Campone M, De Laurentiis M, Jhaveri K, et al. for the VERITAC-2 Study Group. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 393(6):556-568, 2025.

Updated 07/16/26